An innovative approach to the care of patients on phase I and phase II clinical trials: the role of the experimental therapeutics nurse.
The tremendous strides in survival rates for childhood malignancies in large part can be attributed to the clinical trial mechanism. New and innovative therapies are being developed in the laboratory in an attempt to find a cure for those children who have relapsed or have refractory disease. Phase I and phase II clinical trials move this science from the laboratory to the patient's bedside. With increasing frequency, the oncology staff nurse may be managing the care of a patient receiving a phase I or phase II study drug. Administration of these agents goes beyond what is familiar, requires specialized knowledge, and demands a skill set beyond what is required for standard oncology care. At The Children's Hospital of Philadelphia, the role of the experimental therapeutics nurse was created in an effort to improve the process for identification, treatment, and follow-up of patients receiving these therapies. The broader role of nursing in clinical trials, the multidisciplinary challenges of experimental therapies, and the development of an innovative approach to caring for patients on phase I/II studies are discussed.
Carlson
Claire
C
The Children's Hospital of Philadelphia, USA. carlsoncl@email.chop.edu
Reilly
Maureen
M
Hitchens
Anne
A
D002648:Child; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006776:Hospitals, Pediatric; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000451:nursing; D009859:Oncology Nursing; D005791:Patient Care / Q000379:methods*; D010371:Pediatric Nursing; D015143:Philadelphia; D036302:Therapeutic Human Experimentation; D035703:Therapies, Investigational / Q000451:nursing*